September 20, 2010 (Barcelona, Spain) — Adding the anticholinergic agent tiotropium bromide (Spiriva, Boehringer-Ingelheim and Pfizer), approved for the treatment of chronic obstructive pulmonary ...

Boehringer Ingelheim announced that Spiriva Respimat (tiotropium bromide) is now available for the long-term maintenance treatment of asthma in patients ages ≥12 years. Boehringer Ingelheim announced ...

Tiotropium (as bromide monohydrate) 18mcg/cap; dry pwd in caps for oral inhalation; with inhaler device. Spiriva Handihaler consists of Spiriva capsules and the Handihaler device. Spiriva capsules ...

RIDGEFIELD, Conn., August 19, 2014 – Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for the fixed-dose ...

Further tiotropium + olodaterol FDC data on patient outcomes such as quality of life are due to report later this year SAN DIEGO--(BUSINESS WIRE)--For media outside of the US, the UK & Canada only ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. Spiriva Respimat contains the active ingredient tiotropium. Spiriva ...

In a 48-week placebo-controlled trial, 398 patients 12 to 17 years of age with moderate asthma were randomly assigned to receive tiotropium 5 μg, tiotropium 2.5 μg, or an identical placebo delivered ...

RIDGEFIELD, Conn. -- Boehringer Ingelheim today presented the first data from the pivotal Phase III TONADO™ 1&2 studies (NCT01431274 / NCT01431287) for the fixed-dose combination (FDC) of tiotropium ...

Using bronchodilators early on in patients with chronic obstructive pulmonary disease (COPD) is increasingly understood to be an important therapeutic intervention to improve quality of life, inhibit ...

Boehringer Ingelheim today announced the submission of Marketing Authorisation Applications (MAAs) in 31 European countries for the once-daily fixed-dose combination of tiotropium + olodaterol ...

RIDGEFIELD, Conn., Aug. 19, 2014 /PRNewswire/ -- Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for the ...

For media outside of the US, the UK & Canada only Boehringer Ingelheim today announced the first Phase III data for the once-daily fixed-dose combination of tiotropium and olodaterol. Results from the ...